老年冠心病患者血清Lp-PLA2、hs-CRP、IL-27及MMP-9水平与Gensini积分的相关性研究*

目的:探讨老年冠心病患者血清脂蛋白相关磷脂酶A2(Lp-PLA2)、高敏C反应蛋白(hs-CRP)、白细胞介素-27(IL-27)及基质金属蛋白酶-9(MMP-9)水平与Gensini积分的相关性。方法:选取2015年10月至2018年2月我院收治的冠心病患者142例为研究对象,将所有患者按照不同的冠心病类型分为不稳定型心绞痛(UAP)组54例、稳定型心绞痛(SAP)组40例和急性心肌梗死(AMI)组48例。同时根据患者Gensini积分将其分为轻度47例、中度51例和重度44例。比较不同冠心病类型、不同严重程度的Lp-PLA2、hs-CRP、IL-27、MMP-9水平及Gensini积分,并分析冠心病患者上述指标水平与Gensini积分的相关性。结果:AMI组患者Lp-PLA2、hs-CRP、IL-27、MMP-9水平及Gensini积分均高于UAP组和SAP组,且UAP组高于SAP组(P0.05)。重度患者Lp-PLA2、hs-CRP、IL-27、MMP-9水平及Gensini积分均高于中度和轻度患者,且中度患者高于轻度患者(P0.05)。经Spearman相关性分析结果显示,冠心病患者Lp-PLA2、hs-CRP、IL-27、MMP-9水平与Gensini积分均呈正相关(P0.05)。结论:老年冠心病患者Lp-PLA2、hs-CRP、IL-27及MMP-9水平与患者冠状动脉病变Gensini积分均呈正相关。临床根据Lp-PLA2、hs-CRP、IL-27及MMP-9水平的变化,有助于评估老年冠心病患者的病情严重程度。     

老年急性冠脉综合征患者血尿酸与血脂、HCY及hs-CRP水平的关系研究

目的:研究老年急性冠脉综合征(ACS)患者血尿酸(UA)与血脂、同型半胱氨酸(HCY)及超敏C反应蛋白(hs-CRP)水平的关系。方法:选择从2014年2月到2017年9月在重庆三峡中心医院接受治疗的老年ACS患者59例作为研究对象。急性心肌梗死(AMI)患者32例,即为AMI组;不稳定型心绞痛(UAP)患者27例,即为UAP组。另选同期30例在我院接受体检的健康志愿者作为对照组,对比各组UA、HCY、hs-CRP水平以及血脂水平,并分析患者UA与血脂、HCY及hs-CRP水平的相关性。结果:AMI组和UAP组的UA、HCY及hs-CRP水平均高于对照组,且AMI组又高于UAP组(P0.05)。AMI组和UAP组的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)水平均高于对照组,AMI组又高于UAP组(P0.05);AMI组和UAP组的高密度脂蛋白(HDL)水平低于对照组,且AMI组又低于UAP组(P0.05)。根据Spearman法分析相关性可知,患者UA与HCY、hs-CRP、TC、TG及LDL均呈正相关,与HDL呈负相关(P0.05)。结论:老年ACS患者UA、HCY、hs-CRP、TC、TG及LDL水平均较高,HDL水平较低,且UA与血脂、HCY以及hs-CRP均具有较好的相关性,临床可尝试将其作为重点监测靶点,从而应用于ACS患者的诊治。     

急性冠脉综合征患者PAPP-A基因IVS6+95(C/G)多态性与血浆PAPP-A水平及斑块性质的相关性

为研究湖北十堰地区急性冠脉综合征(ACS)患者PAPP-A基因IVS6 +95(C/G)多态性与血浆PAPP-A水平和斑块性质的相关性,随机选择215例ACS患者(包括58例急性心肌梗死(AMI)患者、73例不稳定型心绞痛(UAP)患者和84例稳定型心绞痛(SAP)患者)及142例健康对照者作为研究对象,检测PAPP-A基因IVS6+ 95 (C/G)多态性和血浆PAPP-A浓度,并进行统计学分析.结果显示,AMI组、UAP组和SAP组的PAPP-A浓度具有极显著差异(p＜0.01),在稳定性斑块和易损性斑块组间的PAPP-A浓度亦具有极显著差异(p＜0.01);AMI组、UAP组和SAP组与对照组间的基因型频率和等位基因频率具有显著差异(p＜0.05);在ACS组和对照组中,组内各类基因型人群的血浆PAPP-A浓度的差异不显著(p＞0.05).结果表明,PAPP-A基因IVS6+ 95多态性与急性冠脉综合征患者密切相关,血浆PAPP-A浓度与斑块性质相关,能够反映ACS患者斑块的易损性,是ACS患者危险分层的标志物.     

血清IgE水平与冠心病的相关性分析

目的:探讨血清IgE水平与冠心病的相关性。方法:将我院收治的135例患者根据冠脉造影结果分为冠心病组(CHD)和非冠心病组(non-CHD),冠心病组根据临床症状分为稳定型心绞痛组(SAP)、不稳定型心绞痛组(UAP)和急性心肌梗死组(AMI),动脉堵塞程度用Gensini评分量化,采用SIMENS BNII全自动免疫散射比浊仪测定总IgE水平。比较CHD和non-CHD组患者及SAP、UAP和AMI组患者血清IgE水平的差异,并进一步分析血清IgE等级与冠心病Gensini积分的相关性。结果:non-CHD患者血清IgE水平(32.3(13.5,61)KU/L)明显低于CHD患者(69(26.4,169)KU/L)(P=0.001),UAP和AMI患者血清IgE水平(78.6(37.0,191.0)KU/L、118.5(75.3,148.1)KU/L)均显著高于SAP组(36.7(20.7,96.7)KU/L)(P=0.034和P=0.001),且多支血病变组患者血清IgE水平(67.2(30.9,249.0)KU/L)显著高于单支血管病变患者(34.6(18.1,59.0)KU/L)(P=0.039)。IgE水平根据四分位间距分为四个等级,随着IgE分级水平增加冠心病Gensini积分增加。结论:冠心病患者血清IgE水平升高,且与冠心病类型和血管堵塞程度都存在显著相关性,可能辅助冠心病的诊断及病情监测。     

Elevated Levels of Oxidized Low-Density Lipoprotein Correlate Positively with C-Reactive Protein in Patients with Acute Coronary Syndrome

The relationship between oxidized low-density lipoprotein (Ox-LDL) and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) is unknown. We, therefore, measured serum levels of Ox-LDL and high-sensitivity (hs)-CRP in 90 ACS patients, 45 stable angina pectoris (SAP) patients, and 66 healthy controls using sandwich ELISA. ACS patients were subdivided into: (1) acute myocardial infarction (AMI; n = 45); (2) unstable angina pectoris (UAP; n = 45) groups. In AMI patients, Ox-LDL (177.5 mmol/l) and hs-CRP (25.40 mg/l) levels were significantly higher (P < 0.01) than in UAP (Ox-LDL:107.5 mmol/l, hs-CRP:10.7 mg/l) and SAP (Ox-LDL:82.3 mmol/l, hs-CRP:2.10 mg/l) patients as well as controls (Ox-LDL:41.4 mmol/l, hs-CRP:1.76 mg/l). Ox-LDL/hs-CRP levels in UAP patients were significantly higher (P < 0.01) than in SAP patients and controls. Importantly, a positive correlation was found between Ox-LDL and CRP (r = 0.622; P < 0.01) levels. Serum levels of total, HDL, and LDL cholesterol did not differ among these patient groups. In conclusion, our data show that Ox-LDL and hs-CRP levels correlate positively in ACS patients, supporting the hypothesis that Ox-LDL and CRP may play a direct role in promoting the inflammatory component of atherosclerosis in these individuals. We suggest that Ox-LDL/CRP elevated levels may serve as markers of the severity of the disease in evaluation and management of ACS patients.     

冠心病患者体内瘦素与高敏C反应蛋白检测的临床意义

目的:研究血清瘦素(LP)与高敏C反应蛋白(hsCRP)水平在冠心病患者体内的变化,及临床检测意义。方法:入选住院确诊的冠心病住院患者168例,对照组62例。外周血白细胞(WBC)水平应用全自动血细胞计数仪检测,血清高敏C反应蛋白水平应用比浊法检测,并血清瘦素水平用酶联免疫吸附法检测,分析瘦素与高敏C反应蛋白和外周血白细胞的关系。结果:(1)冠心病稳定型心绞痛组、不稳定型心绞痛组及急性心肌梗死组血清瘦素、高敏C反应蛋白和外周血白细胞水平显著高于对照组(均P0.05)。(2)血浆瘦素、高敏C反应蛋白及外周血白细胞水平在稳定型心绞痛组、不稳定型心绞痛组及急性心肌梗死组三组间依次增高,差异有统计学意义(均P0.05)。(3)简单相关分析显示瘦素与高敏C反应蛋白和外周血白细胞相关,r值分别为5.241和4.025,均P0.05。结论:瘦素与高敏C反应蛋白和外周血白细胞关系密切,可能通过炎症反应参与冠心病的发生。     

血浆及外周血中性粒细胞内髓过氧化物酶水平在冠心病临床诊断中的意义

目的:研究冠心病患者外周循环血中性粒细胞中髓过氧化物酶指数(MPXI)和血浆中髓过氧化物酶(MPO)浓度的改变及两者间相关性,探讨两者在冠心病临床诊断中的意义。方法:随机选取冠心病患者55例,按病情严重程度分为急性冠脉综征(ACS)组35例[包括不稳定心绞痛(UAP)组21例和急性心肌梗死(AMI)组14例]和稳定心绞痛(SAP)组20例,同时随机选取健康体检人员60例为正常对照组;采用ADVIA2120全自动血细胞分析仪检测MPXI,取血浆用ELISA法检测血浆MPO浓度。结果:ACS组MPXI(6.31±4.24)显著高于SAP组(3.38±2.14)和对照组(2.78±2.12),差异有统计学意义(P<0.05);SAP组MPXI高于正常对照组,差异无统计学意义(P>0.05)。ACS组血浆中MPO(1204.07±838.61 pmol/L)显著高于SAP组(755.97±426.23 pmol/L)和对照组(290.45±99.87 pmol/L),差异有统计学意义(P<0.05);SAP组MPO显著高于正常对照组,差异有统计学意义(P<0.05)。SAP组MPXI与MPO无相关性(r=0.424,P>0.05),ACS组MPXI与MPO呈负相关(r=-0.536,P<0.05)。结论:MPXI和MPO在冠心病的诊断中有意义,MPXI与血浆中MPO在ACS组中呈负相关。     

血清可溶性CD147的含量与冠状动脉粥样硬化性心脏病 发病风险的关联分析

目的：探讨血清可溶性CD147（sCD147）的含量与冠状动脉粥样硬化性心脏病（CAHD）发病风险的关系并初步探讨其临床 应用价值。方法：收集130 例CAHD（包括50 例稳定性心绞痛（SAP）、46 例不稳定性心绞痛（UAP）、34 例急性心肌梗死（AMI）） 和130 例年龄、性别与冠心病患者相匹配的健康志愿者的外周血样本,应用双抗体夹心ELISA检测各组血清sCD147 的表达水 平,比较分析血清sCD147 水平与CAHD的临床相关性,并绘制研究对象工作特征（ROC）曲线。结果：CAHD 患者血清sCD147 含量（AMI、UAP 及SAP 组中位数分别为3.35 ug·L-1、2.72 ug·L-1和2.66 滋g·L-1）显著高于对照组（中位数为1.64 ug·L-1,P < 0.001）,其中AMI组明显高于UAP及SAP组（P值分别为0.008、0.006）。血清sCD147 含量与CAHD患者TG、LDL-C 及AIP 显 著正相关（P值分别为0.021、0.035 及0.039）。以健康对照为参照,与sCD147 含量低的个体相比,sCD147 含量高的个体CAHD 发 病风险显著上升（校正比值比为2.18;95%可信区间为1.49-2.96）,且高的sCD147 含量与CAHD发病风险之间存在显著的剂量 依赖关系（P < 0.001）。用血清sCD147 含量绘制ROC 曲线,曲线下面积为0.761（95%可信区间为0.702-0.82）。以血清sCD147 含 量≥ 2.71 ug·L-1为临界值,用血清sCD147 含量诊断CAHD的敏感度为73.1%,特异度为76.9%。结论：血清sCD147 含量与 CAHD 发病风险显著正相关,可作为CAHD发病监测及CAHD早期诊断的检测指标。     

急性冠状动脉综合症患者血浆溶血磷脂酸及基质金属蛋白酶-9水平的检测及意义

目的：探讨急性冠状动脉综合症（acute coronary syndromes,ACS）患者血浆溶血磷脂酸（lysophatidic acid,LPA）及基质金属蛋白酶-9（matrix metalloproteinase-9,MMP．9）水平的变化,探讨其在ACS中可能的临床意义。方法：入选100例ACS患者,根据病情将其分为怠性心肌梗死（AMI）组50例,不稳定型心绞痛（UAP）组50例,并入选40例健康者作为对照组,分别用无机磷定量法和酶联免疫吸附测定法测定血浆LPA、MMP-9水平。结果：AMI组血浆LPA、MMP-9水平显著高于UAP组（LPA：3．29±0．42vs2．67±0．37;MMP-9：481．7±86．5VS237．85±65．34,P〈0．01）并且两组均显著高于对照组（LPA：1．82±0．31;MMP-9：87．42±23．85P〈0．01）;LPA与MMP-9水平呈正相关（r=O．224,P〈0．05）。结论：UIA与MMP-9可能是提示不稳定斑块的形成、破裂,进而导致急性冠状动脉综合征的危险信号。     

Innate immunity markers in culprit plaques of acute myocardial infarction or stable angina

We analyzed the innate immunity markers, C-reactive protein (CRP), serum amyloid P component (SAP) and pentraxin-3 (PTX-3), and metalloproteinase-9 (MMP-9) in coronary atherectomy tissues obtained from patients with acute ST elevation myocardial infarction (STEMI) (n=27) or stable angina (n=15). The relative areas immunopositive for CRP and SAP were similar in the two groups. In contrast, the proportion of areas immunopositive for PTX-3 and MMP-9 was higher in the STEMI group, compared to the stable angina group. PTX-3 or MMP-9-stained areas largely overlapped with those positive for CD68. We concluded that PTX-3 plays a role in the pathogenesis of STEMI.     

心房颤动抗凝治疗的进展

心房颤动（简称房颤）是临床上常见的心律失常之一,是缺血性卒中的一个重要独立危险因素,房颤可使各年龄段脑卒中的危险增加4～5倍。因此,对于房颤患者,尤其是老年患者,无论是哪一型的房颤,均应进行抗凝治疗。近年来,房颤抗凝治疗取得了一定的成果,现概述如下。     

Serum apolipoprotein B level and other parameters of lipid metabolism in patients after myocardial infarction

Total cholesterol, triglycerides, cholesterol HDL, and apolipoproteins B were determined in 117 patients including 87 patients with recent myocardial infarction. Cholesterol LDL was calculated from Friedewald-Frederickson 's equation. Calculated mean values of the above parameters of lipid metabolism were within normal values. In the group of patients with recent myocardial infarction the following subgroups were distinguished: male patients who under went myocardial infarction under 40 years of life (subgroup A), male patients who underwent myocardial infarction at the age over 40 years (subgroup B), and female patients (subgroup C). No statistically significant differences between male and female patients were noted. A sole lipid index differentiating subgroups A and B was serum apolipoprotein B level (1.5 g/L in subgroup A, and 1.16 g/L in subgroup B). Discrimination analysis has shown also a higher value of this parameter in distinguishing the subjects who underwent myocardial infarction in the young age.     

不同类型冠心病患者血清Hcy、TBIL、hs-CRP、尿酸的表达及临床意义

目的:探讨不同类型冠心病患者血清同型半胱氨酸(Hcy)、总胆红素(TBIL)、高敏C反应蛋白(hs-CRP)、尿酸的水平及临床意义。方法:选取首都医科大学附属北京地坛医院2015年9月-2018年7月收治的冠心病患者132例为冠心病组,根据临床诊断分为稳定型心绞痛52例(SAP组)、不稳定型心绞痛42例(UAP组)、急性心肌梗死38例(AMI组),另选取50例同时期于我院体检的健康志愿者为对照组,检测各组Hcy、TBIL、hs-CRP、尿酸的水平,采用Pearson相关分析Hcy、TBIL、hs-CRP、尿酸水平之间的相关性,采用Logistic回归分析冠心病的影响因素。结果:冠心病组患者的血清Hcy、hs-CRP、尿酸水平显著高于对照组,TBIL水平显著低于对照组(P0.05)。AMI、UAP组患者的血清Hcy、hs-CRP、尿酸水平显著高于SAP组,TBIL水平显著低于SAP组(P0.05),且AMI组患者的血清Hcy、hs-CRP、尿酸水平显著高于UAP组,TBIL水平显著低于UAP组(P0.05)。经Pearson相关分析显示,Hcy与hs-CRP、尿酸呈正相关,与TBIL呈负相关,hs-CRP与尿酸呈正相关(P0.05),TBIL与hs-CRP、尿酸无明显相关性(P0.05)。经Logistic回归分析显示,Hcy、hs-CRP、尿酸、高血压、糖尿病均是冠心病的独立危险因素(P0.05),TBIL是冠心病的保护因素(P0.05)。结论:冠心病患者血清Hcy、hs-CRP、尿酸水平升高,TBIL水平降低,Hcy、TBIL、hs-CRP、尿酸与患者的病情相关,也是冠心病的影响因素。     

阿托伐他汀对急性心肌梗塞患者hs-CRP及血脂水平的影响

目的:研究阿托伐他汀对急性心肌梗塞患者超敏C反应蛋白(hs-CRP)及血脂水平的影响。方法:选取2012年1月到2015年1月我院收治的急性心肌梗塞患者80例,按照随机数字表法将患者分为研究组和对照组,每组40例,对照组给予常规治疗,研究组在对照组的基础上给予阿托伐他汀治疗,比较治疗前后两组hs-CRP和总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平。结果:两组治疗后hs-CRP较治疗前显著降低(P0.05),且研究组治疗后hs-CRP显著低于对照组,(P0.05);治疗后两组TC、TG和LDL-C显著低于治疗前,HDL-C显著高于治疗前(P0.05),且治疗后研究组TC、TG和LDL-C显著低于对照组,HDL-C显著高于对照组(P0.05)。结论:阿托伐他汀治疗急性心肌梗塞具有较好的效果,能有效降低hs-CRP水平,改善患者血脂水平。     

急性心肌梗死患者PCI治疗后抑郁对心率变异性、内皮功能及不良心血管事件发生率的影响

目的:探讨急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)治疗后抑郁对心率变异性(HRV)、内皮功能及不良心血管事件(MACE)发生率的影响。方法:选择2017年1月-2018年12月期间在本院接受PCI治疗的AMI患者117例作为研究对象,根据PCI术后出院当日的抑郁自评量表(SDS)评分值将其分为抑郁组(评分值≥53分)41例、非抑郁组(评分值<53分)76例。对比两组患者HRV相关指标[正常RR间期标准差(SDNN)、5 min内正常RR间期平均值标准差(SDANN)、相邻正常RR间期差值均方的平方根(RMSSD)、总功率(TP)、低频功率(LF)、高频功率(HF)、低频功率与高频功率比值(LF/HF)]、内皮功能指标[内皮依赖性血管舒张功能(FMD)、非内皮依赖性血管舒张功能(NMD)]水平差异,记录两组随访期内MACE发生情况。结果:PCI术后出院当日,抑郁组患者的HRV时域指标SDNN、SDANN、RMSSD水平低于非抑郁组患者;频域指标中LF、LF/HF的水平高于非抑郁组,HF的水平低于非抑郁组(P<0.05),两组患者TP水平的差异无统计学意义(P>0.05)。抑郁组患者的FMD、NMD水平均低于非抑郁组患者,差异有统计学意义(P<0.05)。随访期内,抑郁组患者的MACE总发生率、再发心肌梗死发生率高于非抑郁组,差异有统计学意义(P<0.05)。两组患者顽固性心绞痛、新发心肌梗死、心力衰竭、心源性死亡发生率的差异无统计学意义(P>0.05)。结论:AMI患者PCI后合并抑郁可能对心血管系统造成负面影响并最终增加MACE的发生风险。     

A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease

Visfatin, a newly identified proinflammatory adipokine, has been linked to coronary artery disease (CAD). The ?1535C>T polymorphism (rs61330082) located in the visfatin gene promoter is reportedly associated with proinflammatory status. However, it is unclear whether this polymorphism correlates with plasma levels of inflammatory markers including visfatin, hs-CRP, IL-6 and TNF-?? in CAD patients. The present study was to investigate the potential association of the ?1535C>T polymorphism with plasma levels of visfatin, IL-6, C reactive protein (hs-CRP) and TNF-?? in patients with CAD. We conducted a hospital based study with 171 CAD patients to examine the association between the ?1535C>T polymorphism and plasma levels of visfatin, hs-CRP, IL-6 and TNF-??. Plasma visfatin levels were markedly different between patients with stable angina pectoris (SAP, 11.91 ± 0.70 ng/l) and those with unstable angina pectoris (UAP, 17.49 ± 0.20 ng/l) or acute myocardial infarction (AMI, 16.63 ± 0.22 ng/l; SAP versus UAP or AMI, P < 0.05). Compared with the CC genotype, variant genotypes CT and TT correlated with significantly lower levels of visfatin, hs-CRP, IL-6 and TNF-?? in the SAP group (P < 0.05), with lower levels of hs-CRP and IL-6 in the UAP group (P < 0.05), and with lower levels of visfatin in the AMI group (P < 0.05) after adjustment for age, gender, smoking, hypertension, diabetes, dyslipidemia and medication. Our results suggest that the ?1535C>T polymorphism is associated with decreased plasma levels of inflammatory markers in CAD patients, reflecting that this polymorphism might provide a useful marker for predicting the development of CAD events.     

Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease

The oxidative hypothesis of atherosclerosis proposes that oxidative modification of low density lipoprotein (LDL) plays a critical role in atherogenesis. The evaluation of LDL oxidation in vivo is therefore very important. However, data concerning the evaluation of the above biochemical marker is very limited in clinical practice. This study was conducted to test the hypothesis that plasma levels of ox-LDL reflect atherosclerosis and determine the clinical significance in the measurement of circulating ox-LDL and autoantibodies against them as well as their correlation with homocysteine and lipid parameters in the diagnosis and severity of coronary heart disease. A total of 273 individuals were examined: 41 suffering from unstable angina pectoris (UAP), 62 from stable angina pectoris (SAP) and 170 healthy control subjects. We used a sensitive method for detecting ox-LDL that is based on a direct sandwich technique (ELISA) in which two monoclonal antibodies are directed against separate antigenic determinants on the oxidized apolipoprotein-B molecule along with another enzyme immunoassay designed to determine human antibodies to oxidized LDL (anti-oxLDL) directly in serum. Total homocysteine (HCY) was evaluated by means of a fully automated fluorescence polarization immunoassay. Patients with UAP exhibited marked elevations in oxLDL levels as compared to patients with SAP (161.2 +/- 28.4 vs. 119.2 +/- 26.6, p < 0.001) and the control subjects (67 +/- 18.8, p < 0.001). The difference in oxLDL levels between patients with SAP and the control group was also statistically significant. Similarly, patients with UAP showed marked elevations in anti-oxLDL antibodies compared to both patients with SAP (602.2 +/- 62.2 vs. 510.8 +/- 50.3,p < 0.001) and control subjects (368 +/- 79.6, p < 0.001). The difference in anti-oxLDL levels between patients with SAP and the controls was also statistically significant. OxLDL levels were not correlated with age in any of the groups studied. Triglycerides, LDL-cholesterol and total cholesterol were elevated in patients with UAP as opposed to patients with SAP and the control subjects, while HDL levels were elevated in the control subjects when compared to patients with SAP and UAP. Homocysteine levels were elevated in patients suffering from UAP and SAP when compared to healthy subjects. Patients with UAP or SAP did not differ on homocysteine levels. Our findings demonstrate the presence of oxLDL in vivo, its strong association with coronary artery disease as well as with the severity of the clinical presentation.     

冠脉PCI治疗后血浆脂蛋白相关磷脂酶A2与基质金属蛋白酶-9水平的变化及临床意义

目的:探讨冠脉经皮冠状动脉介入(PCI)治疗后血浆脂蛋白相关磷脂酶A2(LP-PLA2)与基质金属蛋白酶-9(MMP-9)水平的变化及其临床意义。方法:选择150例急性冠脉综合征(ACS)患者、128例稳定型心绞痛(SAP)患者及100例健康者分为作为ACS组、SAP组及对照组。比较三组入院时血浆MMP-9、LP-PLA2水平及ACS组经PCI治疗前后血浆MMP-9、LP-PLA2水平的变化。结果:与对照组比较,SAP组与ACS组的血浆MMP-9、LP-PLA2水平均明显增高(P0.05);与SAP组比较,ACS组明显增高(P0.05)。与术前比较,ACS组术后血浆MMP-9、LP-PLA2水平明显降低(P0.05)。MMP-9与LP-PLA2在ACS组血浆中呈显著正相关(r=0.617,P0.05),在SAP组与对照组中无相关性(P0.05)。结论:冠脉病变程度越严重,血浆MMP-9和LP-PLA2水平更高;PCI治疗后冠脉斑块趋于稳定,血浆MMP-9和LP-PLA2水平降低,且二者有相关性,提示MMP-9和LP-PLA2参与冠状动脉粥样硬化的发病与发展,且对预测ACS高危人群及评价疗效有一定的临床价值。     

血清可溶性CD147的含量与冠状动脉粥样硬化性心脏病发病风险的关联分析

目的：探讨血清可溶性CD147（sCD147）的含量与冠状动脉粥样硬化性心脏病（CAHD）发病风险的关系并初步探讨其临床应用价值。方法：收集130例CAHD（包括50例稳定性心绞痛（SAP）、46例不稳定性心绞痛（UAP）、34例急性心肌梗死（AMI））和130例年龄、性别与冠心病患者相匹配的健康志愿者的外周血样本,应用双抗体夹心ELISA检测各组血清sCD147的表达水平,比较分析血清sCD147水平与CAHD的临床相关性,并绘制研究对象工作特征（ROC）曲线。结果：CAHD患者血清sCD147含量（AMI、UAP及SAP组中位数分别为3.35μg·L-1、2.72μg·L-1和2.66μg·L-1）显著高于对照组（中位数为1.64μg·L-1,P〈0.001）,其中AMI组明显高于UAP及SAP组（P值分别为0.008、0.006）。血清sCD147含量与CAHD患者TG、LDL-C及AIP显著正相关（P值分别为0.021、0.035及0.039）。以健康对照为参照,与sCD147含量低的个体相比,sCD147含量高的个体CAHD发病风险显著上升（校正比值比为2.18;95%可信区间为1.49-2.96）,且高的sCD147含量与CAHD发病风险之间存在显著的剂量依赖关系（P〈0.001）。用血清sCD147含量绘制ROC曲线,曲线下面积为0.761（95%可信区间为0.702-0.82）。以血清sCD147含量≥2.71μg·L-1为临界值,用血清sCD147含量诊断CAHD的敏感度为73.1%,特异度为76.9%。结论：血清sCD147含量与CAHD发病风险显著正相关,可作为CAHD发病监测及CAHD早期诊断的检测指标。     

High clinical accuracy of asymmetric dimethylarginine and symmetric dimethylarginine in patients with ischemic heart disease

Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) were found in various clinical settings including coronary heart disease. To assess ADMA and SDMA diagnostic validity in patients with different stages of ischemic heart disease, we studied these markers in patients having stable angina pectoris (SAP), unstable angina (USAP), and acute myocardial infarction (AMI). The results were compared with the values of healthy individuals. Plasma ADMA and SDMA levels were measured by high-performance liquid chromatography. In all patient groups both markers were significantly elevated in comparison with control ones (p?<?0.001). In SAP patients, the median ADMA value was 0.75 (0.31–2.73)?μmol/L, and SDMA 1.11 (0.69–0.1.42)?μmol/L, in USAP patients, the marker values were 0.94 (0.34–3.13)?μmol/L and 1.23 (0.88–4.72)?μmol/L, and in AMI patients, 0.98 (0.48–2.01)?μmol/L and 1.26 (0.75–2.93)?μmol/L, while in healthy subjects they were 0.31 (0.17–0.87)?μmol/L and 0.29 (0.20–0.83)?μmol/L, respectively. SDMA was found significantly different in SAP and AMI patients (p?<?0.05). Diagnostic accuracy was determined by receiver operating characteristic (ROC) curve analysis. The highest area under the ROC (AUC) for ADMA was obtained in AMI patients (0.976), while for SDMA in USAP patients (1.000). There was no significant difference between the AUCs. The greatest sensitivity and specificity were found in the USAP group (95.65 and 96.30?% for ADMA, and 100?% for each characteristic of SDMA). Considering these results, SDMA showed better clinical accuracy in assessing ischemic disease, where it could be used as a valid marker and a therapeutic target.